vTv Therapeutics (VTVT) Reports Q2 Loss of $0.47/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. SPY
9. SBUX
10. AXP

Go back to vTv Therapeutics (VTVT) Reports Q2 Loss of $0.47/Share

vTv Therapeutics (VTVT) Announces Completion of Phase 2 LOGRA Enrollment

August 16, 2016 7:26 AM EDT

vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) announced the completion of enrollment of the companys Phase 2 LOGRA (aLlosteric Oral Glp1 Receptor Agonist) study, a randomized, double-blind, placebo-controlled, parallel group trial of TTP273. TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential.

The previous Phase 1b trial of TTP273 showed robust effects on postprandial and fasting glucose. In this study, all doses of TTP273 were well tolerated with no serious adverse events or evidence of significant gastrointestinal side effects.

Last week, vTv announced positive topline... More